Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma

Inclusion Criteria: * Peritoneal carcinomatosis arising from ovarian epithelial carcinoma (stage III or higher), carcinoma of the fallopian tube and primary peritoneal carcinoma. * Residual tumor \< 2.5 mm after completion of cytoreductive surgery. * Aged \< 75 years. * Baseline ECOG 0-1 (Eastern Cooperative Oncologic Group). * Adequate bone marrow function with hemoglobin ? 8 g/dl (after correction for iron deficiency anemia), white blood cell count ? 3,000/mm3, platelets ? 100,000/mm3. * Adequate renal function with creatinine ? 1.5 mg/ dl. * Adequate liver function with bilirubin levels ? 1.5 mg / dl and AST and ALT ? 80 IU / L. * Optimal cardiopulmonary function. * In recurrences, disease-free interval \> 6 months. * Voluntary and signed written informed consent. Exclusion Criteria: * Extraperitoneal tumor disease. * Suboptimal debulking (residual tumor \> 2.5 mm). * Previous history of other malignancies (excluding skin) * Intestinal obstruction at the time of evaluation. * Renal failure. * Heart failure. * Uncontrolled infection. * Pregnant or lactating patients. * In recurrences, disease-free interval \< 6 months.